Company ProfilePremium

Mach7 Technologies Limited

Company Profile Analysis

Ticker: M7T.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Mach7 Technologies Limited - Company showcase

Year Founded & Workforce

2007

230 Employees

Mach7 Technologies Limited logo

Mach7 Technologies Limited Employee Contacts

10 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Mach7 Technologies Limited Overview

Mach7 Technologies is a small-cap, ASX-listed healthcare software company focused on enterprise imaging. Its products manage, orchestrate and display diagnostic images across health systems. The platform has three layers. The first is a Vendor Neutral Archive (VNA) that consolidates DICOM and non-DICOM imaging without proprietary lock-in. The second is the eUnity zero-footprint enterprise diagnostic viewer, acquired with Client Outlook in 2020. The third is a newer suite of "Flamingo" orchestration modules for routing, normalisation, anonymisation and lifecycle management. After a reset year in FY26 under CEO Teri Thomas, recurring revenue reached 84% of a A$27.9M revenue base, while operating costs fell 16%. Management's ambition is to become the "default orchestration platform" in its category, which it also calls the "imaging EMR." The thesis rests on a simple idea: as AI becomes a heavy consumer of imaging data, the vendor-neutral data layer underneath becomes more valuable. Mach7 competes against far larger PACS and enterprise-imaging vendors. It is debt-free but loss-making on a statutory basis.


Company's own description (FY26 Result, 28 Aug 2026)

Mach7 describes itself as a healthcare software company that provides enterprise imaging solutions for modern, AI-enabled healthcare environments. In its own words, the platform comprises a VNA, the eUnity Enterprise Diagnostic Viewer and an expanding set of Flamingo modules. Together these help healthcare organisations build a unified, longitudinal patient record that integrates diagnostic imaging with broader clinical data. The company says it is increasingly aligned with cloud ecosystems such as Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI). Its customers include integrated delivery networks (IDNs), national health systems and specialist imaging providers.

Independent characterisation

Mach7 sits in the imaging IT infrastructure layer of the healthcare software value chain. Below it are imaging modalities (CT, MRI, X-ray, ultrasound, mammography, digital pathology scanners) and departmental PACS. Above it are electronic health records (EHRs, notably Epic and Oracle Health/Cerner) and AI applications. Mach7's job is to make images held in many departmental silos available enterprise-wide, under the customer's control, in standard formats.

The company frames this shift as moving "from storage to orchestration." Its argument is that storing images is becoming a commodity, as cloud object storage gets cheaper and hyperscaler imaging services such as AWS HealthImaging emerge. Normalising, routing and governing imaging data, by contrast, keeps its value. Mach7 explicitly says it is not a diagnostic-AI company. Instead, it presents itself as the infrastructure that delivers AI results to users and makes AI training easier (FY26 Result Presentation).

Business model and revenue model

Revenue mix indicatorFY2022FY2023FY2024FY2025FY2026
Recurring revenue % of total4954727584
Recurring revenue coverage of OPEX %——728088

Mach7 earns revenue from four streams (FY21–FY26 results):

  1. Subscription fees. Term subscriptions, including SaaS and cloud-hosted deployments, recognised over time from First Productive Use (FPU).

  2. Maintenance and support fees. Annual support on perpetual or term licences. Together with subscription, this forms "recurring revenue."

  3. Capital software licence fees. One-off perpetual or term licence sales, recognised on delivery. These are lumpy and milestone-driven.

  4. Professional services. Implementation, data migration, integration and training.

Sources: FY23 Result (FY22–FY23 recurring share); FY25 Result (FY24–FY25 share and OPEX coverage); FY26 Result (FY26).

The model shift is deliberate. Since FY24, Mach7 has steered new North American sales toward multi-year subscriptions rather than capital licences. This lowers near-term recognised revenue but raises predictability. The FY24 transition caused revenue to dip slightly, even though FY24 sales orders were a record A$61.3M TCV (FY24 AGM address, Nov 2024). In FY26, ARR-type sales made up 86% of total sales orders (Appendix 4E, FY26). In Q4 FY26, a long-standing academic customer converted from the historical capital licence model to a five-year, A$2.8M TCV subscription (Q4 FY26 Business Update).

Gross margin is very high, as is typical for software. It was 96% in FY22, 97% in FY23 (FY23 Result) and 93% in FY26 (FY26 Result Presentation). The main cost lines are staff (A$22.6M of A$29.8M operating payments in FY26 per the Appendix 4C), administration (A$4.8M), product/operating costs (A$1.2M) and marketing (A$1.0M).

Customer types and end-markets

Integrated delivery networks and hospital systems (US): Examples include Adventist Health, Sentara Healthcare, Penn State Health, UnityPoint Health, Advocate Aurora Health (historic) and a leading academic medical centre (unnamed). Trinity Health was a customer until its non-renewal in FY26.

National and government health systems: Examples are the Hospital Authority Hong Kong (HAHK) and the US Veterans Health Administration (VHA). Mach7 was a subcontractor on the VHA NextGen PACS programme, which ceased in FY26.

Teleradiology and specialist imaging groups: Examples include AMRADNET (American Radiologist Network Inc.), DocPanel and Diagnostic Imaging Associates (DIA).

Regional and Middle East health systems: These are served through channel partner Allarch.

End-markets: radiology (core), cardiology, oncology, teleradiology, and newly digital pathology. eUnity digital pathology capabilities were showcased at SIIM26 in June 2026, and the Q3 FY26 Presentation cited early traction in this area. Regions served are North America (primary), Asia-Pacific, the Middle East (GCC) and, to a lesser degree, Europe. Mach7 is pursuing MDR compliance and the CE Mark (H1 FY26 Result).

Strategy

Stated strategy themes (FY26 Result and Presentation, 28 Aug 2026; H1 FY26 call)

Vision: to be "the global imaging EMR." Imaging is presented as the last major unstructured, fragmented component of the patient record (H1 FY26 and Q2 FY26 calls).

Theme: "From Archive to Architecture." The aim is to move value capture from storage, which is commoditising, to orchestration (normalising, routing, governing).

Ambition: become the default orchestration platform in its category. The intended routes are broader reach through partners, expansion into more imaging use cases ("-ologies," pathology), greater pricing power, and recognition as the safest long-term choice for customers.

Three-phase horizon: 1. Stabilise. Largely complete: cost base reset, recurring engine protected, leadership rebuilt.

  1. Prove the growth engine. FY27: show operating leverage, with revenue growing faster than OPEX.

  2. Compound and lead. The longer-term ambition.

FY27 KPIs set by management: - ARR growth

  • New customer wins

  • Flamingo module adoption

  • OPEX discipline with a drive to profitability

Strategic initiatives (last 24 months)

InitiativeDateDescriptionStatus
CEO-led strategic review and resetJul 2025 onwardBuy-back paused, cost restructure, new leadership, single product roadmapCompleted in FY26 (A$1.9M restructuring cost)
Customer engagement model ("Flight Crew")FY25–FY26Designated cross-functional teams per customer, executive sponsorship, enterprise business reviewsOperational. KLAS eUnity score 86.6
Flamingo platform launch21 Nov 2025 (RSNA)Modular orchestration platformFirst production go-live at UnityPoint (Q4 FY26); new modules due at RSNA 2026
Next-generation containerised architectureFY26Enables a land-and-expand modular sales motionIn development
AI-assisted software developmentFY26Used to accelerate delivery and improve quality (Q4 FY26 update)Ongoing
Cloud alignment (AWS, OCI)Feb 2025 onwardeUnity on AWS HealthImaging; OCI alignmentOngoing
Partner ecosystem build-outFY2610 partners activated across four categories: strategic alliances, regional resellers, clinical workflow integrators and international partners (Q3 FY26). Includes Dell, AWS, Oracle, Allarch and Howard MedicalExpanding
Epic interoperabilityQ4 FY26eUnity listed in Epic Connection HubAchieved
Digital pathology / "-ologies" expansionH2 FY26eUnity digital pathology capabilities (SIIM26)Early traction cited (Q3 FY26)
Regulatory expansionFY26MDR compliance and CE Mark pathwayIn progress (H1 FY26)
Subscription conversionFY24 onwardCapital-to-subscription transition in North AmericaRecurring share at 84% (FY26)
Capital managementJan 2025 to Mar 2026On-market buy-back (6.3M shares for A$2.2M in FY25). Paused Aug 2025; completion announced Mar 2026Closed

ESG and sustainability commitments

No quantified emissions targets or sustainability-linked initiatives were identified in the documents reviewed.

Guidance and medium-term targets

ItemGuidance / targetOutcome
FY26 revenueAbout 15% below FY25 (Q3 FY26, reaffirmed Q4 FY26)−17% to A$27.9M, described as "in line with" guidance
FY26 OPEXAbout 10% below FY25−16% to A$26.7M, beating guidance
FY27No quantitative revenue or EBITDA guidance identified. Qualitative: operating leverage, ARR growth, new logos, module adoption—
Long-standing targetRecurring revenue to cover 100% of OPEX88% in FY26 (FY24: 72%; FY25: 80%)
FY25 guidance (historic)Revenue and CARR growth of 15–25%; OPEX growth below revenue growthRevenue +16% (met); CARR below the original range (revised to A$30–31M in Jul 2025)

Products & Services

Because Mach7 is a single segment, products are organised below by platform layer.

Layer 1 — Enterprise Data Management (VNA)

AttributeDetail
ProductMach7 Vendor Neutral Archive (VNA), part of the Mach7 Enterprise Imaging Platform, historically branded Enterprise Data Management
DescriptionConsolidates and stores imaging data natively or in DICOM, on-premise, in the cloud or hybrid. No proprietary wrapping and no exit fees (FY26 Presentation)
Key capabilitiesDICOM and non-DICOM ("-ology") ingestion; tag morphing and normalisation; lifecycle management; data migration from legacy PACS; multi-site federation; EHR integration
Core technologyMach7 Management Studio, covered by a US patent awarded for managing enterprise imaging data across distributed health systems (company announcement)
Target customerIDNs, academic medical centres, national health systems
Pricing modelHistorically capital licence plus annual maintenance; now predominantly multi-year subscription
Customer satisfactionKLAS VNA score improved from 68.7 to 73.6 across measurement periods (FY26 Presentation)
Latest versionn.d. A "next-generation containerised architecture" is in development to enable land-and-expand selling

Layer 2 — Enterprise Viewing (eUnity)

AttributeDetail
ProducteUnity Enterprise Diagnostic Viewer, acquired with Client Outlook Inc. in July 2020
DescriptionZero-footprint (browser-based, no client install) diagnostic and clinical image viewer with full image fidelity. Designed as both a viewer and an integration platform
Key capabilitiesDiagnostic reading; clinical and referring-physician viewing; mobile access (patent-awarded mobile technology); EHR image-enablement (Epic); teleradiology workflows; digital pathology viewing (showcased at SIIM26, Jun 2026)
Cloud variantseUnity on AWS HealthImaging (launched 27 Feb 2025); OCI alignment
Ecosystem milestoneListed in Epic Connection Hub (Q4 FY26), making eUnity publicly discoverable by Epic customers for image-enabling EHR workflows
Target customerIDNs, teleradiology groups (e.g. AMRADNET, DocPanel), imaging centres, Epic-based health systems
Pricing modelSubscription (for example, AMRADNET 5-yr A$1.7M TCV) or licence plus support
Customer satisfactionKLAS score of 86.6, above segment average; "would buy again" above 90 vs a KLAS market average of 83.1 (FY26 Presentation)
Deployment speedAMRADNET achieved first productive use in 45 days

Layer 3 — Orchestration (Flamingo modules)

AttributeDetail
ProductFlamingo modular orchestration platform, launched at RSNA 2025 (21 Nov 2025) under the "From Archive to Architecture" theme
DescriptionRules-based routing, normalisation, anonymisation and lifecycle management of imaging data across systems. Positioned as the layer that must orchestrate imaging data before AI can reliably consume it
First deploymentUnityPoint Health, the first production deployment (Q4 FY26). Went live and generated revenue in under half the typical implementation time
RoadmapNew Flamingo modules scheduled to launch at RSNA 2026 with named early-adopter customers (FY26 Presentation)
Pricing modelModular subscription (per-module adoption is a stated FY27 KPI)
Target customerExisting VNA customers (expansion) and new logos seeking AI-ready imaging infrastructure

Workflow and departmental applications

ProductDescriptionStatus
Universal WorklistEnterprise reading worklist used in teleradiology PACS workflows (historic Client Outlook partnership, 2020)Active (latest version n.d.)
Mach7 PACS / Diagnostic Workflow ApplicationsMach7 VNA plus eUnity plus worklist, configured as a PACS replacement (e.g. Adventist Health, 22 hospitals; Sentara PACS "powered by Mach7")Active
Analytic StudioAnalytics module previewed at RSNA 2019Current status n.d.
Tele-imaging platformRoadmap item disclosed in the Q1 FY26 Presentation (Oct 2025)In development

Services

ServiceDescription
Professional servicesImplementation, data migration (e.g. the historic Sentara migration project), integration, training. FY26 revenue about A$3.0M (derived)
Support and maintenanceAnnual support contracts. Included in recurring revenue
Customer success / "Flight Crew"Designated cross-functional teams with executive sponsorship and enterprise business reviews (FY26)

Discontinued or legacy

3D Medical's medical 3D printing distribution business was part of the 2016 merged entity. It is not referenced in recent disclosures, and its current status is n.d.

Financial Narrative

Income statement

Sources and notes: - Revenue, NPAT and NPATA are from the FY22, FY23, FY25 and FY26 Results. FY24 is from the FY24 AGM address and FY25 Result.

  • Gross profit: FY22 and FY23 from the FY23 Result. FY26 is derived from the 93% gross margin in the FY26 Presentation.

  • FY24 OPEX is derived from FY25 OPEX growth of 9%. FY25 OPEX of A$31.8M is from the FY26 Presentation.

  • Reported EBITDA: FY23 from the Wilsons model (2 May 2025); FY24 and FY25 from the FY25 Result.

  • Adjusted EBITDA: FY23 and FY24 from the FY24 AGM address, FY25 and FY26 from the respective Results.

  • Pre-tax income: FY22–FY26 statutory pre-tax figures were n.d. in the documents reviewed. The NPAT figures include material income-tax benefits; for example, FY23 NPAT benefited from a A$3.4M increase in tax benefits (FY23 Result), and the FY26 loss widened partly due to lower tax benefits (Appendix 4E).

EPS from Simply Wall St summary of FY24 results (FY24 −3.3c; FY23 −0.4c). Diluted EPS n.d. Mach7 has never paid a dividend. NTA per share from the Appendix 4E. Implied FY26 basic EPS is about −3.8c (derived: A$8.9M ÷ ≈234M shares) and is not company-reported.

Margins other than gross margin are derived from the table above.

Revenue CAGR: FY22–FY26 is +0.7% p.a. FY21–FY26 is +8.0% p.a. (from FY21 revenue of A$19.0M, FY21 Result). Both are derived.

Commentary. The five-year revenue line is essentially flat, which captures the core investment debate. Between FY22 and FY23, revenue grew on large capital licence deals: the Adventist PACS rollout, HAHK and renewals. In FY24, management deliberately pivoted new sales to subscription, so revenue slipped about 3% even as sales orders hit a record A$61.3M TCV and ARR rose about 30%. FY25 was the payoff year. Recurring revenue rose 20% as subscription contracts reached FPU, and revenue grew 16% to A$33.8M.

FY26 reversed that gain. Two material recurring contracts were lost: the Trinity Health non-renewal and the VHA programme cancellation. Capital licence revenue collapsed 70% to A$1.5M, reflecting conversions to subscription, delayed capital deals in the Middle East and Asia, and lower expansion volumes. Professional services also softened. The underlying "quality" metrics improved: recurring revenue rose to 84% of revenue and covered 88% of OPEX. But the absolute recurring base fell 8%.

The statutory loss widened to A$8.9M. Three things drove this: amortisation of acquired intangibles (the gap between NPAT and NPATA was about A$6.0M in FY26), A$1.9M of restructuring costs, and lower tax benefits.

The company describes H2 FY26 as an inflection. H2 revenue of A$14.3M exceeded H1's A$13.7M despite currency headwinds, adjusted EBITDA improved from −A$2.3M in H1 to about +A$1.4M implied in H2 (derived from the full-year −A$0.9M), and Q2–Q4 operating cash flow was positive.

Balance sheet

Sources and notes: - Cash: FY23–FY24 from the Wilsons model (2 May 2025); FY25 and FY26 from the FY26 Result.

  • Mach7 has carried no borrowings in any period reviewed. The Q4 FY26 Appendix 4C reports nil loan facilities.

  • Total assets and equity for FY25 are from the FY25 Annual Report (filed 28 Oct 2025) as compiled by FinancialFilings.

  • Net current assets of A$20.06M at 30 Jun 2023 are from the H1 FY24 Half Year Report.

  • Goodwill and intangibles are n.d. They are material, given the ≈A$40.9M Client Outlook acquisition and ongoing amortisation (≈A$6.0M p.a. gap between NPAT and NPATA in FY26).

  • FY26 statutory balance sheet totals were n.d. at the time of writing. The decline in NTA/share from 9.8c to 8.0c implies tangible equity of roughly A$19–23M (derived).

Commentary. The balance sheet is Mach7's defining defensive asset. Cash of A$19.9M with no debt equals about 70% of FY26 revenue. On the 6 Jul 2026 market capitalisation (A$69M) it was roughly 29% of market value; on the early-October OTC-implied value (~A$50M) it was about 40%. Cash fell A$3.2M in FY26. The drivers were an operating outflow of A$1.4M (mostly Q1, which included restructuring payments), A$0.9M of capitalised development and PP&E, and a A$0.8M FX translation loss on USD cash (Appendix 4C FY26). Deferred revenue, a key working-capital item for an upfront-billing software company, was n.d. for FY26.

Cash flow

Sources and notes: - Cash receipts: FY22 Result (A$28.2M); FY26 Appendix 4C (A$27.96M).

  • Operating cash flow: FY24 from the Q4 FY24 call (A$3.2M); FY25 from the FY25 Result (A$0.9M; A$0.87M per the Annual Report); FY26 from the Appendix 4C (−A$1.438M).

  • FY23 operating cash flow was positive per company commentary, but the amount was n.d.

  • Capitalised development: FY24 and FY25 from the FY25 Result; FY26 from the Appendix 4C (A$0.847M).

FY24–FY25 free cash flow is derived and excludes PP&E: - Buy-backs: 6.3M shares for A$2.2M in FY25 (FY25 Result). The FY26 YTD financing cash flow was a net +A$12k; buy-back activity was paused from 27 Aug 2025 and completion was announced in Mar 2026.

Q3 and Q4 are from the Q3 and Q4 FY26 updates. Q4 is A$1.063M. Q1 and Q2 are derived from the FY26 total of −A$1.438M, with Q2 described as positive. The Q1/Q2 split is approximate: Q2 was reported positive, so Q1 was roughly −A$3.3M to −A$3.6M. Treat both as indicative.

Ratios

FY25 ratios are derived from FY25 Annual Report totals (assets A$64.2M, equity A$45.6M). Net-debt and interest metrics are not meaningful (n/m) because the company has no debt and net cash. Other ratios await the FY26 Annual Report.

Recurring-revenue KPIs

Sources and notes: - ARR: FY22 Result (A$14.4M), FY23 Result (A$17.0M), FY24 AGM address (A$22.0M), FY26 Presentation (A$23.5M for both FY25 and FY26; FY26 is +7.6% in constant currency).

  • Note the discrepancy: H1 FY25 ARR was reported at A$25.1M and Mar-25 at A$24.4M. The A$23.5M FY25 comparative in the FY26 Presentation appears to reflect the FY25 closing figure, possibly at different FX.

  • CARR: FY23 from the Q4 FY23 update; FY24 from the Q4 FY24 call (A$27.9M).

  • FY25 CARR is shown as derived (A$25.5M ÷ (1 − 8.9%) ≈ A$28.0M, per the Q4 FY26 update). This conflicts with the Jul 2025 guidance of "A$30–31M." The difference likely reflects FX restatement or customer losses after guidance; both figures are noted.

  • Sales orders: FY22 derived from FY23 A$40.3M being up 21%; FY24 from the FY24 AGM address.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue type (AUD Mn)

Revenue type (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Recurring revenue (subscription + maintenance & support)

13.416.321.125.323.4

Capital software licence revenue

10.811.0—5.01.5

Professional services and other (derived)

2.92.8—3.53.0

Non-recurring revenue total (derived)

13.713.88.08.54.5

Total revenue

27.130.129.133.827.9

Growth and contribution (%)

Growth and contribution (%)FY2023FY2024FY2025FY2026

Recurring revenue YoY growth

222920-8

Total revenue YoY growth

11-316-17

Capital licence YoY growth

2——-70

Recurring share of total revenue

54727584

Product share of product revenue (%)

Product share of product revenue (%)FY2024FY2025FY2026

VNA / Enterprise Data Management

606054

eUnity Enterprise Viewer

404046

Income Statement

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Revenue

27.130.129.133.827.9

Gross profit

26.129.1——25.9

Operating expenses (OPEX)

——29.231.826.7

EBITDA (reported, normalised)

—1.7-3.3-1.5—

Adjusted EBITDA (excl. unrealised FX and SBP)

—2.5-2.0-0.3-0.9

NPATA

4.47.2-1.20.4-2.9

Net profit after tax (NPAT)

-4.2-1.0-8.0-6.2-8.9

Per-share metrics (A$ cents)

Per-share metrics (A$ cents)FY2022FY2023FY2024FY2025FY2026

EPS basic

—-0.4-3.3——

Dividends per share

00000

NTA per share

———9.88.0

Margins (%)

Margins (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

9697——93

Adjusted EBITDA margin

—8.3-6.9-0.9-3.2

NPATA margin

16.223.9-4.11.2-10.4

Net margin

-15.5-3.3-27.5-18.3-31.9

Balance Sheet

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Cash and equivalents

—23.426.223.119.9

Total debt

00000

Net debt (negative = net cash)

—-23.4-26.2-23.1-19.9

Total assets

———64.2—

Total equity

———45.6—

Net current assets (working capital)

—20.1———

Cash Flow

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Cash receipts from customers

28.2———28.0

Operating cash flow

——3.20.9-1.4

Capitalised development (intangibles capex)

——0.20.90.8

PP&E capex

————0.1

Free cash flow (OCF minus capex)

——3.00.0-2.4

Share buy-backs

0002.20.0

Dividends paid

00000

Quarterly operating cash flow FY26 (AUD Mn)

Quarterly operating cash flow FY26 (AUD Mn)Q1 FY26Q2 FY26Q3 FY26Q4 FY26

Net cash from operating activities

-3.30.01.21.1

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

ROE % (NPAT / closing equity)

——-13.6—

ROA % (NPAT / closing assets)

——-9.7—

ROIC

————

Debt / equity (x)

0000

Net debt / EBITDA

n/m

n/m

n/m

n/m

Interest coverage

n/m

n/m

n/m

n/m

Asset turnover (x)

——0.53—

Current ratio

————

Cash conversion cycle

————

Key Financials

KPI (AUD Mn)FY2022FY2023FY2024FY2025FY2026

ARR run rate at 30 June

14.417.022.023.523.5

CARR at 30 June

—20.627.928.025.5

Sales orders TCV

33.340.361.3——

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY2024FY2025FY2026

North America

———

Asia-Pacific

———

Middle East

———

Europe / Other

———

Total

29.133.827.9

Share Price & Returns

Reference dateShare price (AUD)Source

Aug 2020 (post-Client Outlook)

1.11

ASX announcement price log

Aug 2023 (FY23 result)

0.78

ASX announcement price log

Aug 2024 (FY24 result)

0.56

ASX announcement price log

Feb 2025 (H1 FY25)

0.44

ASX announcement price log

Oct 2025 (Q1 FY26)

0.295

InvestSMART

Nov 2025 (UnityPoint win)

0.51

ASX announcement price log

Feb 2026 (H1 FY26)

0.34–0.36

ASX price log; Motley Fool

4 May 2026 (CFO change)

0.26

RTTNews

6 Jul 2026

0.295

InvestSMART

2 Oct 2026 (OTC TDMMF US$0.14)

≈0.21 (implied, at about 0.66 AUDUSD)

Yahoo Finance (OTC); ASX quote to be verified

Return metric (%)

1-year

3-year

M7T total share price return (as of Feb 2026)

-12.2—

Valuation Multiples

MultipleAt A$0.295 (Jul 2026)At ≈A$0.21 (implied, Oct 2026)

Market capitalisation (AUD Mn)

69

≈50

Enterprise value (AUD Mn, mcap minus A$19.9M cash)

≈49

≈30

EV / FY26 sales (x)

≈1.8

≈1.1

EV / FY26 recurring revenue (x)

≈2.1

≈1.3

EV / ARR (x)

≈2.1

≈1.3

P/e Details

P/En/m (loss-making)n/m

EV/EBITDA

n/m (negative adj. EBITDA)

n/m

P/B

n.d. (FY26 equity n.d.)

—

Analyst Ratings & Targets

BrokerRatingPrice target (AUD)Date

Morgans

Buy

0.44

Late Apr / May 2026 (after Q3 FY26)

Wilsons

Overweight

0.85 (revised from 1.15)

30 Apr / 2 May 2025 (dated)

TipRanks-recorded analyst

Hold

0.50

Around Aug 2025

Coverage breadth

About 8 analysts cover the stock; about 3 contribute estimates

—

Simply Wall St

Capital Markets

ItemStatus

Dividend history

Never paid a dividend; none recommended or declared for FY26 (Appendix 4E)

Dividend policy

None. Capital retained for growth and selective investment

Buy-back

On-market programme announced 30 Jan 2025, commenced 3 Mar 2025. 6.3M shares bought for A$2.2M in FY25; paused 27 Aug 2025; completion announced Mar 2026. No new authorisation identified

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

Not applicable (no debt, no facilities)

Analyst Conclusions

Management guidance

No quantitative FY27 guidance was identified. Management's stated FY27 priorities are positive customer outcomes, new customer wins, expanding revenue from the installed base, and visible operating leverage. The KPI scorecard comprises ARR growth, new logos, Flamingo module adoption and OPEX discipline. Capital allocation is to remain disciplined, investing selectively where returns are clear (FY26 Result).

Consensus expectations

Not publicly available in the sources reviewed. Simply Wall St (Dec 2025) cited forecast revenue growth of about 10.8% p.a. and continued losses over three years. That pre-dates the FY26 result and should be treated as stale.

Bull case

  1. Operating leverage is already visible. OPEX fell to A$26.7M against an ARR run rate of A$23.5M growing 7.6% in constant currency. Recurring revenue already covers 88% of OPEX. Modest ARR growth (about A$3M) combined with flat costs would close the gap, and with 93% gross margins most incremental revenue drops to profit. H2 FY26 adjusted EBITDA was positive (derived) and operating cash flow was positive in three straight quarters.

  2. Distribution step-change. Epic Connection Hub, Howard Medical (more than 3,700 hospitals), AWS, OCI, Dell and Allarch give a sub-scale vendor reach it could not fund alone. eUnity's 86.6 KLAS score and the 45-day AMRADNET go-live provide differentiated proof points to convert that reach.

  3. Valuation floor and optionality. At an implied EV of about A$30–49M, the market pays only about 1.1–2.1x recurring revenue for a high-margin, debt-free software asset with A$19.9M cash. The CEO previously sold Volpara to a strategic acquirer. Larger imaging players seeking vendor-neutral orchestration could find Mach7 an inexpensive tuck-in.

Bear case

  1. The base is shrinking, not compounding. Revenue is flat over five years (A$27.1M in FY22 vs A$27.9M in FY26). CARR fell 8.9% to A$25.5M, and backlog not yet live is only A$2.0M. Two contract losses in a single year show how fragile a small customer base is.

  2. Execution and leadership risk. The company is on its third CFO in about a year (an interim CFO is in place), and seven senior leaders were appointed in 12 months. Flamingo has one production deployment. The reset narrative must now be proven with numbers. Repeated guidance shortfalls (FY25 CARR, FY26 revenue) have eroded credibility.

  3. Structural squeeze. Hyperscalers commoditise storage while large vendors bundle imaging IT with modalities. Better-capitalised specialists (Sectra, Visage) win marquee replacements. With capitalised development of under A$1M a year, Mach7 risks being out-invested in the AI-orchestration layer it is targeting.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
~Late Oct 2026FY26 Annual Report; Q1 FY27 Appendix 4CRemuneration structure and KPIs; top-20 register; geographic revenue note; Q1 cash flow (seasonally weakest)
Late Nov / Dec 2026RSNA 2026 Flamingo module launch; 2026 AGMNamed early adopters; first module revenue; any board renewal
Q2 FY27 (Jan 2027)Quarterly updateNew logos; ARR above A$24M; CARR stabilisation
Feb 2027H1 FY27 resultYear-on-year revenue growth; positive adjusted EBITDA
OngoingPermanent CFO appointmentLeadership stability
OngoingMiddle East capital deal conversionRevenue upside, or further slippage
OngoingFurther churn disclosuresContract renewals in the installed base
OngoingCorporate activityAny approach given the low EV and CEO track record

Analyst verdict

Mach7 enters FY27 as a cleaner but smaller business. The FY26 reset did what resets should do. Cost fell 16%, recurring revenue rose to 84% of the mix and to 88% coverage of OPEX, operating cash flow turned positive for three quarters, and the balance sheet stayed debt-free with A$19.9M of cash. Product credibility also improved measurably. eUnity's KLAS score of 86.6 sits above the market, the VNA score is climbing, deployments are faster, and the Epic Connection Hub listing is real distribution leverage for a company of this size.

Against that, the hard numbers have gone backwards. Revenue fell 17%, CARR fell 9%, and the statutory loss widened to A$8.9M. Five years of revenue history show essentially no growth. The FY26 losses of Trinity Health and the VHA programme also exposed how much a handful of contracts drive outcomes. Leadership turnover at the CFO level is an unwelcome signal in the very year execution matters most.

The investment case is therefore a binary test of operating leverage. Management has set the right KPIs: ARR growth, new logos, Flamingo adoption and OPEX discipline. The arithmetic is favourable, because a few million dollars of net new ARR on a fixed cost base would make Mach7 sustainably profitable at the EBITDA line. The market, however, is pricing failure. At an implied enterprise value of roughly 1–2x recurring revenue, the shares embed little credit for the reset. That creates asymmetric upside if FY27 shows even modest ARR growth, and strategic optionality given the CEO's exit history.

Our assessment is speculative / high-risk, positive-skew. The balance sheet protects downside in the near term, but conviction requires evidence. The key tests are Flamingo module revenue after RSNA 2026, at least two new enterprise logos, and H1 FY27 revenue growth. Until those arrive, Mach7 remains a show-me turnaround rather than a proven compounder.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleBoard tenureBackgroundIndependence

Robert (Rob) Bazzani

Non-Executive Chairman

Since Jan 2020 (Chair after the Chambers era; exact date n.d.)

More than 30 years in corporate finance and advisory. 21 years at KPMG, including membership of KPMG's National Executive Committee. NED of OFX Group (since Feb 2024) and Keypath Education International (since May 2021). Chair of Risk and Compliance Committee

Independent NED

Teri Thomas

Managing Director & CEO

Since 1 Jul 2025

Former CEO of Volpara Health Technologies (ASX: VHT), where she led a turnaround and sale to Lunit; later Chief Business Officer of Lunit

Executive

Rebecca Thompson

Non-Executive Director; Chair, Audit & Risk Committee

Since Nov 2023 (advisor in the prior year)

Former Head of Investor Relations at CSR Limited (acquired by Saint-Gobain in 2024). BEc (University of Sydney), GradDip Applied Finance & Investment (FINSIA), MAICD

Independent NED

Dr Eliot L. Siegel

Non-Executive Director

Tenure n.d.

Radiologist and imaging-informatics authority. The company website notes a board member of Carestream Health and numerous imaging advisory boards; attribution to Dr Siegel is inferred from the website ordering

Independent NED (assessed)

Executive Leadership Team

NameTitleAppointedNotes

Teri Thomas

MD & CEO

1 Jul 2025

See above

Shawni Hadfield

Interim CFO

4 May 2026

Previously VP Commercial Excellence. Prior CFO experience and SaaS finance expertise (CFO Transition, 4 May 2026)

Brian Wehrle

Chief Technology Officer

6 May 2026

Leads unified product, support and engineering (company press release; FY26 Presentation)

Todd Stallard

EVP Sales & Marketing

FY26 (date n.d.)

Presented at the Q3 FY26 webinar

Paul Jensen

Chief Innovation Officer

Jul 2025

First CIO role (Q4 FY25 Presentation). Current status n.d.

David Madaffri

Chief Operating Officer

——

Françoise Debelak Dixon

Head of Investor Relations

—

IR contact on all FY26 releases

Naomi Lawrie

Company Secretary

24 Jun 2025

Corporate lawyer (Vistra Australia)

Board & Management Changes

DateChangeContext

1 Apr 2025 (effective 30 Jun / 1 Jul 2025)

Mike Lampron (CEO since 2019) steps down; Teri Thomas appointed

Board sought turnaround and commercial-growth experience. Lampron had stabilised the business and delivered cash-flow positivity but not operating leverage

Jul 2025

Paul Jensen appointed Chief Innovation Officer

Innovation and product focus

Oct 2025

Daniel Lee appointed CFO

Replaced the prior CFO (name n.d.); CEO noted more than 500 applicants

4 May 2026

Daniel Lee resigns (family priorities); Shawni Hadfield becomes Interim CFO

Second CFO change in about seven months, a governance monitorable

6 May 2026

Brian Wehrle appointed CTO

Consolidation of engineering and product

Directors' Remuneration

ItemAmountSource

Executive Director (CEO) salary and superannuation, Q4 FY26

A$144,314 for the quarter (≈A$577k annualised, derived)

Q4 FY26 Appendix 4C, section 6

Non-executive directors' fees and superannuation, Q4 FY26

A$77,492 for the quarter (≈A$310k p.a. aggregate, derived)

Q4 FY26 Appendix 4C

CEO short-term incentive (STI), long-term incentive (LTI) and equity grants

n.d. pending FY26 Annual Report

—

Major Shareholders

HolderStakeNotes / source

Microequities Asset Management

Substantial holder; exact % n.d.

Bought about 2.38M shares (Jul 2025) and about 3.23M shares (Nov 2025) per substantial-holder notices compiled by Simply Wall St

Australian Ethical Investment

Substantial holder; exact % n.d.

Bought about 2.57M shares (Oct 2025)

Top 22 shareholders combined

About 50.5%

Simply Wall St ownership summary

Rob Bazzani (Chair)

427,869 shares (indirect) plus 100,000 options

Market Index, as of 30 Mar 2026. Repeated on-market buying in Nov 2025 and Mar 2026

Eliot Siegel (NED)

Bought 112,012 shares (Dec 2024)

Total holding n.d.

Ravi Krishnan (founder)

Historically a significant holder; current % n.d.

—

Competitive Landscape

Key Competitors

CompetitorRelevant productsOverlap with Mach7Positioning vs Mach7

Hyland Software (private)

Acuo VNA, NilRead viewer, Enterprise Imaging suite

VNA and viewer

Long-standing VNA leader with a large content-services installed base

GE HealthCare (NASDAQ: GEHC)

Centricity / True PACS, Enterprise Imaging, VNA

PACS, VNA, viewer

Scale player that bundles imaging IT with modalities

Philips (AMS: PHIA)

Vue PACS, Image Management, IntelliSpace

PACS, VNA, viewer

Scale player; cloud PACS push

Sectra AB (STO: SECT B)

Sectra One Cloud, PACS/VNA, digital pathology

Enterprise imaging, pathology

Strong KLAS performer; consistent winner of US IDN replacements

Pro Medicus / Visage Imaging (ASX: PME)

Visage 7 Enterprise Imaging viewer and Open Archive

Viewer, archive

Market-leading cloud-native viewer in US academic medicine; Mach7's most-cited ASX comparable

Fujifilm Healthcare

Synapse PACS, Synapse VNA

PACS, VNA

Bundled modality and IT vendor

Agfa HealthCare (EBR: AGFB)

Enterprise Imaging Platform

Enterprise imaging

Strong in Europe; restructuring

Intelerad Medical Systems (private)

InteleViewer, PowerServer, Nucleus

PACS, viewer, VNA

Acquisitive mid-market player

Merative (formerly IBM Watson Health imaging)

Merge PACS, iConnect VNA

VNA, PACS

Legacy installed base

Change Healthcare / Optum (UnitedHealth)

Enterprise imaging (legacy McKesson)

VNA, PACS

Legacy installed base

Hyperscaler services (AWS HealthImaging, Google Cloud Healthcare API, Microsoft Azure Health Data Services)

Cloud imaging storage and APIs

Storage layer

Commoditising storage. Both a partner (AWS) and a potential disintermediator

Peer Comparison FY2026

MetricMach7 (FY26, A$)Pro Medicus (FY25, A$)Sectra (latest FY)GE HealthCare (imaging IT, FY25)

Revenue

27.9M

——

Imaging IT not separately disclosed

Revenue growth

-17%———

Gross margin

93%———

EBITDA / EBIT margin

-3.2% (adj. EBITDA)

———

Capitalised R&D intensity (% of revenue)

3.0%———

Net cash

19.9M

———

Recent Developments

--

Company Snapshot

$18M

Revenue

230

Employees

$32.9M

Market Cap

2007

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • High-quality recurring revenue base: Recurring revenue was 84% of FY26 revenue (FY25: 75%; FY22: 49%) and covered 88% of OPEX (FY26 Result)
  • Software-grade gross margin: 93% in FY26; 97% in FY23 (FY26 Presentation; FY23 Result)
  • Debt-free, cash-rich balance sheet: A$19.9M cash, nil debt, no facilities at 30 Jun 2026 (Appendix 4C)
  • Best-in-class viewer satisfaction: eUnity KLAS 86.6 vs a market average of 83.1; "would buy again" above 90 (FY26 Presentation)
  • Restored cash generation: Operating cash flow positive in Q2, Q3 (+A$1.2M) and Q4 FY26 (+A$1.1M)
  • Cost discipline demonstrated: OPEX −16% to A$26.7M vs guidance of about −10% (FY26 Result)
  • Ecosystem validation: eUnity listed in Epic Connection Hub; AWS HealthImaging and OCI alignment (Q4 FY26)

Weaknesses

  • Revenue stagnation: FY22–FY26 revenue CAGR of about 0.7%; FY26 revenue A$27.9M vs A$27.1M in FY22
  • Persistent statutory losses: NPAT negative in every year FY22–FY26; −A$8.9M in FY26
  • Customer concentration: Losing Trinity Health and the VHA programme cut recurring revenue 8% in FY26
  • Sub-scale R&D: Capitalised development only A$0.85M in FY26 (3.0% of revenue)
  • VNA satisfaction lags viewer: VNA KLAS 73.6 vs eUnity 86.6 (FY26 Presentation)
  • Leadership churn: CFO turnover in Oct 2025 and May 2026; seven senior appointments within 12 months
  • Shrinking contracted backlog: CARR A$25.5M, −8.9% YoY; contracted backlog not yet live only A$2.0M (Q4 FY26)

Opportunities

  • Imaging intelligence / orchestration growth: Segment growing 20.7%, with US$514M addressable by FY29 (FY26 Presentation)
  • Flamingo upsell to the installed base: First production deployment at UnityPoint went live in under half the typical time; modules launch at RSNA 2026
  • Epic channel: Connection Hub listing exposes eUnity to Epic's US customer base
  • Indirect distribution: Howard Medical reaches more than 3,700 US hospitals; 10 partners activated (Q3–Q4 FY26)
  • Digital pathology and "-ologies": eUnity pathology showcased at SIIM26; early traction (Q3 FY26)
  • Enterprise imaging replacement cycle: Management cites decades-old infrastructure under review (FY26 Presentation)
  • Europe via MDR / CE Mark: In progress (H1 FY26)

Threats

  • Large-vendor bundling: GE, Philips and Fujifilm bundle imaging IT with modalities
  • Storage commoditisation by hyperscalers: Mach7 itself says storage is commoditising (FY26 Presentation)
  • Government procurement risk: VHA Partial Stop Work Order (Jan 2026) ended a multi-year programme
  • Geopolitical delays: Middle East capital deals delayed by regional conflict (Q3 and Q4 FY26)
  • FX translation: A$0.8M FX loss on cash in FY26; reported "significant currency headwinds"
  • Fast-growing specialist peers: Sectra and Pro Medicus/Visage win large US IDN replacements
  • Market de-rating: OTC 52-week low of US$0.14 (2 Oct 2026); 5-year ASX return about −76% (as of Feb 2026)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Apr 2025CEO transition announced (Lampron to Thomas)Signals a pivot to turnaround and commercial growth
30 Apr 2025Q3 FY25 update: second consecutive quarter of positive operating cash flow (A$2.6M). Wilsons notes a lost contract (revenue impact undisclosed)Early sign of churn risk
Apr 2025Mach7 showcases informatics innovations at SIIM25Product marketing
24 Jun 2025Naomi Lawrie appointed Company SecretaryGovernance housekeeping
1 Jul 2025Teri Thomas starts as MD & CEOLeadership change
10 Jul 2025FY25 guidance updated: revenue A$33–34M, CARR A$30–31M (below the original growth range)CARR miss
29 Jul 2025Q4 FY25: operating cash flow positive; Paul Jensen appointed Chief Innovation Officer—
27 Aug 2025FY25 result: revenue +16% to A$33.8M, adjusted EBITDA −A$0.3M. Buy-back paused pending strategic reviewPeak revenue year; reset begins
~Sep 2025A$5M licence agreement amendment signedContract value support (counterparty n.d.)
Oct 2025Daniel Lee appointed CFOFinance leadership renewal
31 Oct 2025Q1 FY26: CARR A$29.6M, TCV A$2.6M, cash A$18.9M. Commercial transformation and tele-imaging roadmap"Reset quarter"
Nov 2025Response to ASX price query (shares rose about 13%), followed by the UnityPoint Health new logo (shares +9.9% to A$0.51)Market-sensitive new logo
21 Nov 2025RSNA 2025: "From Archive to Architecture" and the Flamingo launchStrategic repositioning
27 Nov 20252025 AGM (virtual)Board: Bazzani, Thomas, Thompson, Siegel
H1 FY26Trinity Health does not renew its contractMaterial recurring revenue loss
Jan 2026VHA Partial Stop Work Order ends NextGen PACS; Phase 2 cancelled (shares −10% to A$0.45)Loss of a marquee federal reference
Jan 2026Q2 FY26 update and call; vision of the "world's imaging EMR"—
27 Feb 2026H1 FY26: revenue A$13.7M (−23%), recurring revenue 85% of revenue, OPEX −6%, cash A$18.5M, MDR/CE Mark progressShares −1.5% to A$0.34
Mar 2026Completion of on-market share buy-backCapital management closed
Mar 2026Chair Bazzani buys shares on market at A$0.27–0.275Insider confidence signal
24 Apr 2026Q3 FY26: operating cash flow +A$1.2M, ARR A$22.8M, CARR A$25.8M, TCV A$6.0M (vs A$4.8M in pcp), cash A$19.2M. FY26 revenue guided about 15% lower; 10 partners activated; digital pathology tractionGuidance reset; cash generation restored
Late Apr / May 2026Morgans reiterates Buy with a A$0.44 price target (shares about A$0.275)Broker support
4 May 2026CFO Daniel Lee resigns; Shawni Hadfield appointed Interim CFO (shares −1.9% to A$0.26)Finance turnover
6 May 2026Brian Wehrle appointed CTOEngineering consolidation
~20 May 2026New customer AMRADNET (5-yr A$1.7M TCV eUnity subscription). Announced as shortening sales and deployment timeframes (shares +12.3% to A$0.33)New logo; 45-day go-live
1–12 Jun 2026SIIM26 participation; eUnity digital pathology capabilities showcasedProduct expansion
Jul 2026Sharewise investor webinar presentationInvestor engagement
29 Jul 2026Q4 FY26: operating cash flow +A$1.1M (third straight positive quarter); A$2.8M academic subscription expansion; UnityPoint live on Flamingo; Howard Medical partnership; eUnity in Epic Connection HubExecution evidence
28 Aug 2026FY26 result: revenue A$27.9M (−17%), recurring revenue 84%, OPEX A$26.7M (−16%), NPAT −A$8.9M, cash A$19.9M; RSM unmodified audit opinionReset year completed
Sep–Oct 2026The OTC line (TDMMF) fell to a 52-week low of US$0.14 on 2 Oct 2026, implying ASX weakness after the resultMarket scepticism toward FY27 delivery
Upcoming, ~late Oct 2026FY26 Annual Report and Q1 FY27 Appendix 4CRemuneration report, top-20 holders, geographic note
Upcoming, late Nov / Dec 2026RSNA 2026: new Flamingo modules with named early adopters; 2026 AGMKey catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue Type: Total revenue rose from AUD 27.1 Mn in FY2022 to AUD 27.9 Mn in FY2026.
Mach7 Technologies Limited — Revenue Type
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue27.130.129.133.827.9
Recurring revenue (subscription + maintenance & support)13.416.321.125.323.4
Capital software licence revenue10.811—51.5
Professional services and other2.92.8—3.53
Non-recurring revenue total13.713.888.54.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Mach7 FY26 Result (ASX, 28 Aug 2026) (investorpa.com)
  2. Mach7 Appendix 4E / Preliminary Final Report FY26 (28 Aug 2026) (investorpa.com)
  3. Mach7 FY26 Result Presentation (28 Aug 2026) (investorpa.com)
  4. StockWire X, FY26 results coverage (28 Aug 2026) (stockwirex.com)
  5. Kalkine Media, FY26 Appendix 4E summary (auditor RSM) (kalkinemedia.com)
  6. Mach7 Q4 FY26 Business Update / Appendix 4C (29 Jul 2026) (investorpa.com)
  7. Mach7 Q3 FY26 Results Presentation (24 Apr 2026) (investorpa.com)
  8. Mach7 H1 FY26 Result Presentation (27 Feb 2026) (investorpa.com)
  9. Mach7 VHA Contract Update (Jan 2026) (investorpa.com)
  10. Mach7 CFO Transition (4 May 2026) (bulletin.webull.com)
  11. RTTNews / Nasdaq on CFO change (nasdaq.com)
  12. Mach7 Q1 FY26 (InvestSMART summary) (investsmart.com.au)
  13. Mach7 FY25 Result (ASX, 27 Aug 2025) (announcements.asx.com.au)
  14. Mach7 FY25 Results Highlights / Presentation / Preliminary Final · investorpa.com · investorpa.com
  15. Mach7 Q4 FY25 Presentation (29 Jul 2025) (investorpa.com)
  16. Mach7 H1 FY25 Result (investorpa.com)
  17. Mach7 CEO Transition (1 Apr 2025) (investorpa.com)
  18. Mach7 FY24 AGM address (Nov 2024) (announcements.asx.com.au)
  19. Mach7 FY23 Result (31 Aug 2023) (announcements.asx.com.au)
  20. Mach7 Q4 FY23 Business Update (announcements.asx.com.au)
  21. Mach7 FY22 Result (29 Aug 2022) (asx.com.au)
  22. Mach7 FY21 Result (23 Aug 2021) (asx.com.au)
  23. Client Outlook acquisition completion (14 Jul 2020) (mach7t.com)
  24. Gadens deal profile, Client Outlook capital raise (gadens.com)
  25. Mach7 A$20M Placement (3 Dec 2019) (mach7t.com)
  26. Mach7 Board Changes (20 Jun 2019) (mach7t.com)
  27. Mach7 2016 AGM Chairman's Address (3D Medical merger) (mach7t.com)
  28. AuntMinnie, Mach7 restructuring (2018/19) (auntminnie.com)
  29. Wilsons broker note (2 May 2025) (asx.com.au)
  30. Morgans view via Motley Fool / Webull (2026) (webull.com.au)
  31. Mach7 Board of Directors (company website) (mach7t.com)
  32. Mach7 2025 AGM transcript (Seeking Alpha) (seekingalpha.com)
  33. Mach7 Q1 FY26 earnings call transcript (Seeking Alpha) (seekingalpha.com)
  34. Market Index, Robert Bazzani director profile (marketindex.com.au)
  35. Simply Wall St ownership (substantial holder transactions) (simplywall.st)
  36. FinancialFilings, FY25 Annual Report figures (financialfilings.com)
  37. InvestSMART M7T share price (Jul 2026) (investsmart.com.au)
  38. Yahoo Finance TDMMF (OTC, Oct 2026) (finance.yahoo.com)
  39. Motley Fool M7T quote and returns (Feb 2026) (fool.com)
  40. StockLight M7T announcement archive (stocklight.com)
  41. Mach7 SIIM26 press release (Jun 2026) (tissuepathology.com)
  42. Mach7 news page (mach7t.com)
  43. Simply Wall St FY24 earnings summary (simplywall.st)
  44. TipRanks, A$4.6M contracts (Dec 2024) (tipranks.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.